These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 7927413)

  • 1. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy.
    Abe Y; Horiuchi A; Miyake M; Kimura S
    Immunol Rev; 1994 Jun; 139():5-19. PubMed ID: 7927413
    [No Abstract]   [Full Text] [Related]  

  • 2. Dose and outcomes in primary immunodeficiency disorders.
    Bonagura VR
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):7-9. PubMed ID: 25546743
    [No Abstract]   [Full Text] [Related]  

  • 3. Protein-glycan interactions as targets of intravenous/subcutaneous immunoglobulin (IVIg/SCIg) preparations.
    von Gunten S
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):151-2. PubMed ID: 25546801
    [No Abstract]   [Full Text] [Related]  

  • 4. Advances of intravenous immunoglobulin G in modulation of anti-fetal immunity in selected at-risk populations: science and therapeutics.
    Christiansen OB
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):120-2. PubMed ID: 25546787
    [No Abstract]   [Full Text] [Related]  

  • 5. Intravenous immunoglobulin therapy: indications, potential side effects, and treatment guidelines.
    Suez D
    J Intraven Nurs; 1995; 18(4):178-90. PubMed ID: 7629638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 7th International Immunoglobulin Conference: Poster presentations.
    Warnatz K; Ballow M; Stangel M; Bril V
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):162. PubMed ID: 25546805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Europe immunoglobulin map.
    Šedivá A; Chapel H; Gardulf A;
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):141-3. PubMed ID: 25546797
    [No Abstract]   [Full Text] [Related]  

  • 8. The question of when and how. Foreword.
    Alam R
    Immunol Allergy Clin North Am; 2008 Nov; 28(4):xiii-xiv. PubMed ID: 18940568
    [No Abstract]   [Full Text] [Related]  

  • 9. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency.
    Berger M
    Immunol Allergy Clin North Am; 2008 May; 28(2):413-37, x. PubMed ID: 18424340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous immunoglobulin treatment of immunodeficiency. Preface.
    Roifman CM
    Immunol Allergy Clin North Am; 2008 Nov; 28(4):xv-xvi. PubMed ID: 18940569
    [No Abstract]   [Full Text] [Related]  

  • 11. Intravenous immunoglobulin G in the treatment of autoimmune bullous disease.
    Czernik A
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):118-9. PubMed ID: 25546786
    [No Abstract]   [Full Text] [Related]  

  • 12. Reversible Hypogammaglobulinemia in 2 Pediatric Patients With Primary Immunodeficiency.
    Pasic S
    J Investig Allergol Clin Immunol; 2017; 27(5):320-321. PubMed ID: 29057740
    [No Abstract]   [Full Text] [Related]  

  • 13. 7(th) International Immunoglobulin Conference: Poster presentations.
    Warnatz K; Ballow M; Stangel M; Bril V
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):139-40. PubMed ID: 25546796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogen-specific IgG antibody levels in immunodeficient patients receiving immunoglobulin replacement do not provide additional benefit to therapeutic management over total serum IgG.
    Chua I; Lagos M; Charalambous BM; Workman S; Chee R; Grimbacher B
    J Allergy Clin Immunol; 2011 Jun; 127(6):1410-1. PubMed ID: 21376379
    [No Abstract]   [Full Text] [Related]  

  • 15. Neutralizing antibodies to granulocyte-macrophage colony-stimulating factor, interleukin-1alpha and interferon-alpha but not other cytokines in human immunoglobulin preparations.
    Wadhwa M; Meager A; Dilger P; Bird C; Dolman C; Das RG; Thorpe R
    Immunology; 2000 Jan; 99(1):113-23. PubMed ID: 10651949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Is there any clinical significance to anti-IgA antibodies which appear in patients with immunodeficiencies treated with intravenous gamma globulin?].
    Ferreira A; Cruz García Rodríguez M; Martín J; Fontán G
    Sangre (Barc); 1995 Jun; 40(3):171-3. PubMed ID: 7570266
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunoglobulin deficiency syndromes and therapy.
    Huston DP; Kavanaugh AF; Rohane PW; Huston MM
    J Allergy Clin Immunol; 1991 Jan; 87(1 Pt 1):1-17. PubMed ID: 1704022
    [No Abstract]   [Full Text] [Related]  

  • 18. Characterization and potential clinical applications of autoantibodies against cytokines.
    de Lemos Rieper C; Galle P; Hansen MB
    Cytokine Growth Factor Rev; 2009 Feb; 20(1):61-75. PubMed ID: 19213592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 7th International Immunoglobulin Conference: Immunomodulation.
    Danieli MG; Shoenfeld Y
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):123. PubMed ID: 25546788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the contents of the magic draft IVIg?
    Seite JF; Shoenfeld Y; Youinou P; Hillion S
    Autoimmun Rev; 2008 Jun; 7(6):435-9. PubMed ID: 18558358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.